非布司他与硫嘌呤抗代谢药药物相互作用:FAERS与文献综述
结果发现骨髓抑制事件,中位1.6个月出现,多数需住院和输血,停药后多可缓解。结论支持现行非布司他说明书禁止与AZA或6-MP联用。
要点
- 非布司他与硫唑嘌呤或巯嘌呤联用可导致骨髓抑制。
- 中位1.6个月出现不良事件,多数需住院和血制品输注。
- 停药后多数事件缓解,支持说明书禁止联用。
核心结论
- 非布司他与硫唑嘌呤或巯嘌呤联用可导致临床显著的骨髓抑制不良事件。
- 现行非布司他说明书禁止与硫唑嘌呤或巯嘌呤同时使用,本病例系列支持该禁忌。
研究设计与样本
- 病例系列,数据来源于美国FDA不良事件报告系统(FAERS)和已发表医学文献。
主要发现
- 从联合用药开始至事件发现的中位时间为1.6个月。
临床怎么用
- 临床应避免非布司他与硫唑嘌呤或巯嘌呤联用,遵循说明书禁忌。
- 如患者需同时使用,应密切监测骨髓抑制相关指标。
局限性
- 硫嘌呤单药治疗本身也可能引起骨髓抑制。
- 未考察免疫抑制并发症对真实世界 morbidity 和 mortality 的贡献。
- FAERS数据受自愿报告性质限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a known drug interaction (DI) between xanthine oxidase (XO) inhibitors and the thiopurine immunosuppressants, azathioprine (AZA) and mercaptopurine (6-MP). Xanthine oxidase inhibition increases concentrations of AZA and 6-MP active metabolites, possibly resulting in myelosuppression. When allopurinol is used with AZA or 6-MP, dose reduction of AZA or 6-MP is recommended. Febuxostat is a newer XO inhibitor approved for the treatment of gout. OBJECTIVE: To determine the clinical impact of the febuxostat-thiopurine DI. DESIGN AND SETTING: Case series derived from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) and published medical literature. PATIENTS: Nineteen patients who received concomitant febuxostat and either AZA or 6-MP. MEASUREMENTS: Laboratory and clinical data. RESULTS: Nineteen cases reporting myelosuppressive events were identified in patients receiving febuxostat with AZA or 6-MP. Eighteen cases were treated with the combination of AZA and febuxostat. A median of 1.6 months elapsed from initiation of the drug combination until discovery of the event. Sixteen cases required hospitalization; 15 reported administration of blood products. Thirteen cases reported resolution of the event with discontinuation of both drugs, two reported discontinuation of the thiopurine only, and one reported discontinuation of febuxostat only. LIMITATIONS: Thiopurine monotherapy may cause myelosuppression. Complications of immunosuppression that may contribute to the real-world morbidity and mortality associated with the febuxostat-thiopurine DI were not examined. Finally, FAERS data are limited by the voluntary nature of reporting. CONCLUSION: Current febuxostat labeling contraindicates concomitant administration of febuxostat with either AZA or 6-MP. This case series demonstrates that the DI can result in clinically significant adverse events and is supportive of current febuxostat labeling.
引用
- Logan JK, Wickramaratne Senarath Yapa S, Harinstein L, et al. Drug Interaction Between Febuxostat and Thiopurine Antimetabolites: A Review of the FDA Adverse Event Reporting System and Medical Literature. Pharmacotherapy. 2020. PMID: 31885095. doi:10.1002/phar.2362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。